Back to results
US 7,425,337 B2Granted
Alphavirus replicon vector systems
AssigneeAlphaVax, Inc.
InventorsJonathan F. Smith, Kurt I. Kamrud, Jonathan O. Rayner, Sergey A. Dryga, Ian J. Caley
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions useful in and methods for producing populations of infectious, replication-defective alphavirus replicon particles that contain no replication competent alphavirus particles, as determined by passage on cells in culture. The compositions include helper and replicon nucleic acid molecules that can further reduce the predicted frequency for formation of replication-competent virus and can optimize manufacturing strategies and costs.
Claims34
A recombinant replicon nucleic acid comprising, in order:
- (i) a nucleotide sequence encoding a 5′ alphavirus replication recognition sequence;
- (ii) a nucleotide sequence encoding alphavirus nonstructural proteins nsp1, nsp2 and nsp3;
- (iii) a nucleotide sequence selected from the group consisting of a transcriptional promoter and an internal ribosome entry sequence (IRES);
- (iv) a nucleotide sequence encoding at least one heterologous nucleic acid of interest;
- (v) an internal ribosome entry sequence;
- (vi) a nucleotide sequence encoding alphavirus nonstructural protein nsp4;
- and
- (vii) a nucleotide sequence encoding a 3′ alphavirus replication recognition sequence.
5 more elements
Dependencies are inferred from the claim text.